Bangalore based drug maker Strides Arcolab has announced that the company has secured a tentative approval from the Food and Drug Administration in the US for a new drug application (NDA) with a combination drug containing Lamivudine and Stavudine.
The approval of the drug which is used for the treatment of AIDS, was expedited under the review provisions of the US President's Emergency Plant for AIDS relief (PEPFAR).
According to the company, the approval has taken the company's total number of NDAs and abbreviated new drug application (ANDAs) approval under the PEPFAR programme to 11.
"This approval is yet another significant milestone in the front line of approvals for key HIV/AIDS medicines. This, combined with our pipeline of second line drugs will make us a significant player in the quality, affordable multisource anti-retroviral drugs (ARVs) business segment," said VS Iyer, CEO, India Operations, Strides Arcolab.
The company supplies ARV products to global procurement agencies. The new approval adds to the overall basket of medicines available, said the company.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app